Recently, it has been demonstrated that levels of Dicer could be used as prognostic markers in non-small cell lung cancer (NSCLC) [11] and in breast cancer patients where reduced mRNA expression is significantly associated with poor patient survival [15–16]. This evidence concerns the gene DICER1 and non-small cell lung carcinoma.